Federal inspectors at a manufacturing plant in Harbin, China, discovered a major compliance failure this week that has put American patients at risk. The Food and Drug Administration issued a formal warning letter to Harbin Jixianglong Biotech after inspectors found the company was relabeling active pharmaceutical ingredients from unauthorized sites. The company allegedly attempted to circumvent U.S. import restrictions on semaglutide, the critical component in Ozempic and Wegovy. While Jixianglong was on the government's “green list” of authorized importers, the FDA found they were sourcing ingredients from a facility that was not vetted for safety. This breach comes as the middle class increasingly turns to government-vetted generic medicines to combat rising health costs. The administration recently expanded its generic drug portal to cover 600 essential medicines, offering metabolic access for as little as $86. Protecting the integrity of this supply chain is a moral necessity. When foreign suppliers use deceptive labels to bypass safety protocols, they treat the health of the American family as a secondary concern to their own profit margins.